Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J. Mease¹, Alice B. Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…
Abstract Number: 1716 • 2015 ACR/ARHP Annual Meeting
Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis
Tatiana Makhinova¹, Robert Wood², Derek Tang³, James Piercy², Steve Lobosco⁴, Bradley S. Stolshek⁵ and David J. Harrison⁵, ¹College of Pharmacy, University of Texas at Austin, Austin, TX, ²Adelphi Real World, Macclesfield, United Kingdom, ³Amgen, Inc., Thousand Oaks, CA, ⁴Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁵Amgen Inc., Thousand Oaks, CA
Background/Purpose: Due to the high prevalence of PsA among patients with PsO,1 rheumatologists and dermatologists should recognize early signs and symptoms of joint involvement among…
Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Kim Papp¹, Alan Menter², Howard Sofen³, Stephen Tyring⁴, Jean-Philippe Lacour⁵, Beate Berner⁶, Nathan Bennett⁷, Stella Aslanyan⁷, Mary Flack⁷ and Paul Scholl⁷, ¹Probity Clinical Research, Waterloo, ON, Canada, ²Baylor Research Institute, Dallas, TX, ³Dermatology Research Associates, Los Angeles, CA, ⁴Center for Clinical Studies, Houston, TX, ⁵Dermatology Department, Hôpital de L’Archet, Nice, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…
Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting
Pregnancy in Psoriatic Arthritis: A Case Series
Maria Mouyis¹, Clare Thornton¹, David Williams^2,3 and Ian Giles⁴, ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Institute for Women’s Health, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Alice B. Gottlieb¹, Kristian Reich², Zailong Wang³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…
Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 3163 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Uyen Sa D.T. Nguyen¹, Yuqing Zhang², Na Lu³, Qiong Louie-Gao⁴, Jingbo Niu⁵, David T. Felson⁵, Michael P. Lavalley⁶, Thorvardur Love^7,8, Maureen Dubreuil⁴, Jeffrey A. Sparks⁹, Elizabeth W. Karlson¹⁰ and Hyon K. Choi³, ¹Orthopedics & Physical Rehabilation, Univerity of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁶Biostatistics, Boston University, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ¹⁰Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Smoking is a strong risk factor of psoriasis, but a previous study has suggested that smoking protects against the development of psoriatic arthritis (PsA)…
Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Aman Sharma¹, Sushant Mishra², Sunil Dogra³ and Harish Kancharla², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Internal Medicine,, PGIMER,, Chandigarh, India, ³Department of Dermatology, PGIMER,, Chandigarh, India
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…
Abstract Number: 2099 • 2014 ACR/ARHP Annual Meeting
Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset
Remy Pollock¹, Fatima Abji¹, Husain Shakil¹, Kun Liang², Vinod Chandran¹ and Dafna D. Gladman^1,3, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a potentially destructive disease that develops in about 30% of patients with cutaneous psoriasis. Biomarkers that can predict which psoriasis…
Abstract Number: 1915 • 2014 ACR/ARHP Annual Meeting
IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R⁺/CD4⁺ and γδ T Cells
Erika Suzuki¹, Ritu Sarin², Emanual Maverakis¹ and Iannis E. Adamopoulos², ¹University of California at Davis, Sacramento, CA, ²Internal Medicine, University of California at Davis, Sacramento, CA
Background/Purpose: IL-17 is elevated in both the lesional skin and arthritic joints of psoriatic arthritis (PsA) patients. Although the IL-23/IL-17 axis has been linked with…
Abstract Number: 1851 • 2014 ACR/ARHP Annual Meeting
Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Robert Kalb¹, David Fiorentino², Mark Lebwohl³, Craig Leonardi⁴, John Toole⁵, Kavitha Goyal⁶, Steve Calabro⁶, Wayne Langholff⁷ and Steve Fakharzadeh⁸, ¹SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, ²Dermatology, Stanford University, Redwood City, CA, ³Mount Sinai Medical Center, New York, NY, ⁴Central Dermatology, St. Louis, MO, ⁵University of Manitoba, Dermadvances Research, Winnipeg, MB, Canada, ⁶Janssen Services, LLC, Horsham, PA, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Janssen Services, LLC, Spring House, PA
Background/Purpose To report the cumulative rates of serious infections in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a multicenter, longitudinal, observational…
Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
M. Elaine Husni¹, Danielle Brennan², WH Wilson Tang³ and Stanley Hazen³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiology, CCF, Cleveland, OH
Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity. Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].